Response rates and toxicity profile of neoadjuvant immunotherapy in early-stage triple negative breast cancer (TNBC) - Multi institute experience

被引：0
|
作者：
Khalid, F. [1 ]
Attia, M. [2 ]
Mehmood, T. [3 ]
Shah, N. [2 ]
Baki, M. [1 ]
机构：
[1] East & North Hertfordshire NHS Trust, Lister Hosp, Stevenage, England
[2] East & North Hertfordshire, Mt Vernon Canc Ctr, Northwood, England
[3] Univ Hosp Northamptonshire NHS Grp, Kettering, England
来源：
CLINICAL ONCOLOGY | 2025年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)
    Michaels, Elena
    Chen, Nan
    Nanda, Rita
    CLINICAL BREAST CANCER, 2024, 24 (04) : 263 - 270
  • [32] A propensity-matched cohort study of neoadjuvant immunotherapy combined with chemotherapy versus neoadjuvant chemotherapy for early-stage triple-negative breast cancer
    Zheng, Chunhui
    Wang, Yongsheng
    Qi, Yingxue
    Song, Yunjie
    Yin, Xiangyu
    Luo, Ningning
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [33] THE ROLE OF IMMUNOTHERAPY IN THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER (TNBC)
    Rugo, Hope S.
    BREAST, 2017, 36 : S29 - S30
  • [34] EFFICACY OF ADJUVANT VERSUS NEOADJUVANT CHEMOTHERAPY IN HISPANIC/LATINO WOMEN WITH EARLY STAGE, TRIPLE NEGATIVE BREAST CANCER (TNBC)
    Philipovskiy, A.
    Corral, J.
    Heydariana, R.
    Gaur, S.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2019, 67 (02) : 593 - 593
  • [35] Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2+Breast Cancer
    Phadke, Sneha
    CURRENT ONCOLOGY REPORTS, 2022, 24 (12) : 1779 - 1789
  • [36] Receptor discordance after neoadjuvant chemotherapy with pembrolizumab in early-stage triple-negative breast cancer
    LeVee, Alexis
    Wong, Megan
    Flores, Sarah
    Ruel, Nora
    McArthur, Heather
    Waisman, James
    Mortimer, Joanne
    CANCER RESEARCH, 2024, 84 (09)
  • [37] Optimization of Neoadjuvant Therapy for Early-Stage Triple-Negative and HER2 + Breast Cancer
    Sneha Phadke
    Current Oncology Reports, 2022, 24 : 1779 - 1789
  • [38] PARTNER Trial: Neoadjuvant olaparib in triple negative breast cancer (TNBC)
    Abraham, Jean E.
    Pinilla, Karen
    Grybowicz, Louise
    Dayimu, Alimu
    Demiris, Nikolaos
    Harvey, Caron
    Drewett, Lynsey M.
    Lucey, Rebecca
    Fulton, Alexander
    Roberts, Anne N.
    Worley, Joanna R.
    Chhabra, Anita
    Qian, Wendi
    Hardy, Richard M.
    Chan, Stephen
    Hickish, Tamas
    Tripathi, Devashish
    Venkitaraman, Ramachandran
    Persic, Mojca
    Aslam, Shahzeena
    Glassman, Daniel
    Raj, Sanjay
    Borley, Annabel
    Braybrooke, Jeremy P.
    Sutherland, Stephanie
    Staples, Emma
    Scott, Lucy C.
    Davies, Mark
    Palmer, Cheryl A.
    Moody, Margaret
    Churn, Mark J.
    Newby, Jacqueline C.
    Mukesh, B. Mukesh
    Chakrabarti, Amitabha
    Roylance, Rebecca R.
    Schouten, Philip C.
    Levitt, Nicola
    McAdam, Karen
    Armstrong, Anne C.
    Copson, Ellen R.
    McMurtry, Emma
    Tischkowitz, Marc
    Provenzano, Elena
    Earl, Helena
    CANCER RESEARCH, 2024, 84 (07)
  • [39] Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC).
    Yam, Clinton
    Alatrash, Gheath
    Yen, Er-Yen
    Garber, Haven
    Philips, Anne V.
    Huo, Lei
    Yang, Fei
    Bassett, Roland L.
    Sun, Xiangjie
    Cuentas, Edwin Roger Parra
    Symmans, William Fraser
    Seth, Sahil
    White, Jason B.
    Rauch, Gaiane M.
    Damodaran, Senthil
    Litton, Jennifer Keating
    Wargo, Jennifer Ann
    Hortobagyi, Gabriel N.
    Moulder, Stacy L.
    Mittendor, Elizabeth A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Clinical and pathological response to neoadjuvant chemotherapy (NCT) in patients with triple negative breast cancer (TNBC)
    Krivorotko, P.
    Zhiltsova, E.
    Gigolaeva, L.
    Emelyanov, A.
    Pesotsky, R.
    Ereschenko, S.
    Levsghenko, V.
    Nikolaev, K.
    Komayachov, A.
    Ivanova, O.
    Tabagua, T.
    Zernov, K.
    Ivanov, V.
    Aseeva, Z.
    Bessonov, A.
    Semiglazov, V.
    BREAST, 2021, 56 : S52 - S52
12345